These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21387266)

  • 21. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
    Gick U; Rochlitz C; Mingrone W; Pestalozzi B; Rauch D; Ballabeni P; Lanz D; Hess V; Aebi S
    Oncology; 2006; 71(1-2):54-60. PubMed ID: 17344671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
    Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
    J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients.
    Ghosn M; Kattan J; Farhat F; Younes F; Gasmi J
    Anticancer Res; 2006; 26(3B):2451-6. PubMed ID: 16821631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
    Schwartzberg LS; Arena FP; Mintzer DM; Epperson AL; Walker MS
    Clin Breast Cancer; 2012 Apr; 12(2):87-93. PubMed ID: 22154117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
    Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Rudas M; Mader RM; Gnant M; Zielinski CC; Steger GG
    J Clin Oncol; 2007 Sep; 25(25):3853-8. PubMed ID: 17679724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
    Perez EA; Hillman DW; Dentchev T; Le-Lindqwister NA; Geeraerts LH; Fitch TR; Liu H; Graham DL; Kahanic SP; Gross HM; Patel TA; Palmieri FM; Dueck AC
    Ann Oncol; 2010 Feb; 21(2):269-274. PubMed ID: 19901014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
    Dellapasqua S; Bertolini F; Bagnardi V; Campagnoli E; Scarano E; Torrisi R; Shaked Y; Mancuso P; Goldhirsch A; Rocca A; Pietri E; Colleoni M
    J Clin Oncol; 2008 Oct; 26(30):4899-905. PubMed ID: 18794539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
    Osako T; Ito Y; Takahashi S; Tokudome N; Iwase T; Hatake K
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):159-64. PubMed ID: 17882419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
    Finek J; Holubec L; Svoboda T; Sefrhansova L; Pavlikova I; Votavova M; Sediva M; Filip S; Kozevnikova R; Kormunda S
    Anticancer Res; 2009 Feb; 29(2):667-70. PubMed ID: 19331218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
    Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
    Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
    Greil R; Moik M; Reitsamer R; Ressler S; Stoll M; Namberger K; Menzel C; Mlineritsch B
    Eur J Surg Oncol; 2009 Oct; 35(10):1048-54. PubMed ID: 19250795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
    Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
    J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
    Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
    Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
    Gradishar WJ; Meza LA; Amin B; Samid D; Hill T; Chen YM; Lower EE; Marcom PK
    J Clin Oncol; 2004 Jun; 22(12):2321-7. PubMed ID: 15197193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
    Puthillath A; Mashtare T; Wilding G; Khushalani N; Steinbrenner L; Ross ME; Romano K; Wisniewski M; Fakih MG
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):242-8. PubMed ID: 19081732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
    Villanueva C; Awada A; Campone M; Machiels JP; Besse T; Magherini E; Dubin F; Semiond D; Pivot X
    Eur J Cancer; 2011 May; 47(7):1037-45. PubMed ID: 21339064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.